Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target.

attention deficit hyperactivity disorder (ADHD) channelopathies hypokalemic periodic paralysis lidocaine premenstrual dysphoric disorder (PMDD)

Journal

Psychopharmacology bulletin
ISSN: 2472-2448
Titre abrégé: Psychopharmacol Bull
Pays: United States
ID NLM: 0101123

Informations de publication

Date de publication:
27 Jun 2022
Historique:
pmc-release: 27 06 2023
pubmed: 12 7 2022
medline: 14 7 2022
entrez: 11 7 2022
Statut: ppublish

Résumé

The mechanism of many neuropsychiatric disorders remains unknown, but the ineffectiveness of the sodium channel blocker lidocaine has been suggested to be a biomarker for Attention Deficit Hyperactivity Disorder (ADHD) and a severe form of Premenstrual Syndrome (PMS) that is considered psychiatric. We conducted single-arm double-blind clinical trials to test whether lidocaine ineffectiveness can be used as a biomarker to identify people with these conditions and provide a clue as to the molecular mechanism and potential psychopharmacological intervention. We developed a noninvasive taste test for lidocaine ineffectiveness, validated by comparing lidocaine injections to pain testing in 12 subjects, and assessed it in individuals with ADHD and PMS. Lidocaine ineffectiveness had a strong association in women with ADHD + PMS in a sample of 53 subjects and controls (p < 0.001). These results suggest the possibility of the biological understanding of the combination of ADHD and PMS that is characteristic of the psychiatric disorder Premenstrual Dysphoric Disorder (PMDD). These results and comparison to family pedigrees of a neuromuscular channelopathy with overlapping symptoms suggest the possibility that the clinical phenotype in PMDD is produced by sensory overstimulation, and amenable to molecular understanding and treatment.

Identifiants

pubmed: 35815177
pmc: PMC9235314

Substances chimiques

Lidocaine 98PI200987

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-30

Subventions

Organisme : NICHD NIH HHS
ID : R43 HD094628
Pays : United States

Informations de copyright

Copyright © 1964–2022 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Auteurs

Mark Mintz (M)

Mintz M, MD, NeurAbilities Healthcare, NJ.

Victor Badner (V)

Badner, DMD MPH, Department of Dentistry, Jacobi Medical Center, NY.

Lynn K Feldman (LK)

Feldman, PhenoSolve Inc., MA.

Pnina Mintz (P)

Mintz P, PhD., NeurAbilities Healthcare, NJ.

Mana Saraghi (M)

Saraghi, DMD, Department of Dentistry, Jacobi Medical Center, NY.

Jonathan Diaz (J)

Diaz, Department of Dentistry, Jacobi Medical Center, NY.

Irina Mezhebovsky (I)

Mezhebovsky, MD, Boston Clinical Trials, MA.

Irene Axelrod (I)

Axelrod, RN, Boston Clinical Trials, MA.

Joseph Gleeson (J)

Gleeson, MD, Departments of Neurosciences and Pediatrics, University of California San Diego, CA.

Chang Liu (C)

Liu, Departments of Neurosciences and Pediatrics, University of California San Diego, CA.

Cathy Smith (C)

Smith, NeurAbilities Healthcare, NJ.

Helen Chow (H)

Chow, Boston Clinical Trials, MA.

David Zurakowski (D)

Zurakowski, PhD, Departments of Anesthesiology and Surgery, Boston Childrens Hospital, Harvard Medical School, Boston, MA.

Michael M Segal (MM)

Segal, MD PhD, PhenoSolve Inc., MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH